On September 20th, according to KKR, the innovative biopharmaceutical company Wuxi Laitakang has successfully completed Series A and Series A+ financing. The Series A round was led by KKR, with CICC Capital's CICC Norsgar Fund participating; the Series A+ round was led by Huagai Capital, with Shenzhen Capital Group and CICC Strategy participating. The financing will mainly be used to accelerate the clinical transformation of the company's myeloid cell bridging technology
